10-Q: United Health Products Faces FDA Hurdles, Seeks Financing

United Health Products reports no revenue for the period, continues to address FDA regulatory concerns, and highlights substantial doubt about its going concern status while securing financing.

Summary

• United Health Products (UHP) reported no revenue for the three and six months ended June 30, 2026, as it continues to focus on obtaining FDA Premarket Approval (PMA) for its CelluSTAT Hemostatic Gauze.
• The company received a Deficiencies Letter from the FDA regarding its PMA application and a Warning Letter concerning violations during a prior clinical study. UHP has submitted Corrective and Preventative Actions (CAPAs) and is undergoing a GCP Audit.
• Financing activities included securing a $250,000 net proceeds convertible note from Alumni Capital and entering into an Any Market Purchase Agreement (AMPA) with Alumni for up to $4,000,000 in common stock purchases.
• The company reported a net loss of $284,140 for the three months ended June 30, 2026, and $599,982 for the six months ended June 30, 2026.
• As of June 30, 2026, the company had cash and cash equivalents of $24,495 and a negative working capital of $4,123,570.
• There is substantial doubt about the company's ability to continue as a going concern due to recurring net losses and negative working capital.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a negative sentiment due to the company's continued lack of revenue, ongoing regulatory challenges with the FDA, and substantial doubt about its ability to continue as a going concern, despite efforts to secure financing.

Positives

• Secured $250,000 in net proceeds from a convertible note with Alumni Capital.
• Entered into an Any Market Purchase Agreement (AMPA) with Alumni Capital for potential future equity purchases up to $4,000,000.
• Reduced operating expenses by $101,506 for the three-month period and $1,332,611 for the six-month period compared to the prior year, primarily due to decreased R&D and consulting expenses.
• Received FDA approval for a proposed collaboration with an established hemostatic device company to serve as a substitute Sponsor in a new pivotal IDE study.
• Engaged NAMSA, a global CRO, to serve as Sponsor in the planned clinical study, allowing it to proceed concurrently with efforts to resolve the FDA Warning Letter.

Negatives

• Reported zero revenue for both the three and six-month periods ended June 30, 2026.
• The company has substantial doubt about its ability to continue as a going concern due to recurring net losses and negative working capital.
• Received a Warning Letter from the FDA detailing five violations related to a prior clinical study.
• The company's cash and cash equivalents were only $24,495 as of June 30, 2026.
• Negative working capital of $4,123,570 as of June 30, 2026.
• The timing to resolve the FDA Warning Letter is uncertain.

Risks

• The company's ability to continue as a going concern is subject to substantial doubt due to recurring net losses and negative working capital.
• The FDA has issued a Warning Letter regarding violations in a prior clinical study, and the timing of its resolution is uncertain.
• There is no assurance that the company will reach an agreement with any party to serve as Sponsor for a new pivotal IDE study or that its planned PMA application will be approved.
• The company has not yet attained a level of operations to meet its current overhead expenses.
• The sale of additional equity or convertible debt securities would be dilutive to existing shareholders.

Future Outlook

The company's primary strategy is to obtain FDA Premarket Approval (PMA) for its CelluSTAT Hemostatic Gauze for Class III human surgical markets. This process is ongoing and faces regulatory challenges, including an FDA Warning Letter. The company is exploring options such as a sale or merger with an industry leader or commercial partnerships. The ability to continue as a going concern is dependent on securing adequate financing and resolving regulatory issues.

Management Comments

• "We are continuing on our path to seek FDA Premarket Approval (PMA) for our CelluSTAT Hemostatic Gauze products to implement our business strategy."
• "The timing to resolve the FDA Warning Letter is uncertain and we may not proceed with a Premarket Approval application to the FDA until its resolution."
• "There can be no assurance that we will reach an agreement with any party to serve as Sponsor of such a study or that our planned PMA application will be approved."
• "We do not intend to pursue the full commercialization of our products independently nor to remain an independent company in the long term."

Industry Context

StockSavvy.ai notes that United Health Products operates in the competitive medical device sector, specifically wound care and hemostatic agents. The company's focus on obtaining Class III PMA for its CelluSTAT product targets a high-value market segment. However, the significant regulatory hurdles with the FDA, as evidenced by the Warning Letter and deficiencies, are a major impediment and place the company at a disadvantage compared to established players with approved products.

Comparison to Industry Standards

• The company's lack of revenue and ongoing struggle to obtain FDA approval for its Class III hemostatic gauze contrasts sharply with industry leaders who have established product lines and consistent revenue streams in the surgical hemostatic market.
• Competitors such as Ethicon (Johnson & Johnson), B. Braun, and C. R. Bard (BD) offer a range of FDA-approved hemostatic agents for surgical use, demonstrating established market presence and regulatory success that UHP has yet to achieve.
• The company's reliance on external financing and related party loans highlights a financial structure less robust than that of larger, publicly traded medical device companies that typically fund operations through operating cash flow or more conventional debt/equity markets.
• The significant delays and complexities in navigating the FDA's PMA process for a Class III device are common but underscore the high bar for entry and the need for rigorous clinical data and compliance, areas where UHP has faced documented challenges.

Related Party Transactions

• Convertible notes payable to related parties (CEO Brian Thom and Director Robert Denser) totaling $500,000 (net of discount) as of June 30, 2026.
• Accrued interest on related party convertible notes was $304,685 as of June 30, 2026.
• Note payable to CEO Brian Thom for $250,000, advanced in 2025, with potential repayment tied to capital raising activities.
• Promissory note to CEO Brian Thom for $277,778, converted from accrued compensation, with a 15% interest rate and maturity in December 2027.
• Accrued interest on related party notes payable was $5,813 as of June 30, 2026.

Stakeholder Impact

• Shareholders face continued dilution risk from potential future equity issuances and the ongoing lack of revenue and profitability.
• Creditors and lenders face increased risk due to the company's substantial doubt about its ability to continue as a going concern.
• Employees may face uncertainty regarding job security given the company's financial condition and regulatory challenges.
• Potential partners or acquirers may be deterred by the ongoing FDA regulatory issues and the company's financial precariousness.

Next Steps

• Continue efforts to resolve the FDA Warning Letter and address deficiencies in the PMA application.
• Complete the GCP Audit of processes, procedures, and personnel by the end of October 2026.
• Work with NAMSA to develop and submit an Investigational Device Exemption (IDE) application for a new pivotal study.
• Evaluate potential sale or merger with an industry leader or pursue commercial partnerships.
• Continue to seek financing to fund operations and development activities.

Key Dates

Recommendation

The company exhibits significant financial distress, with no revenue, substantial doubt about its going concern status, and critical ongoing regulatory challenges with the FDA. While financing has been secured, it is insufficient to overcome the fundamental hurdles. The path to market approval is uncertain and prolonged, making the stock a high-risk investment with limited near-term catalysts for positive valuation change.

Keywords

hemostatic gauze, CelluSTAT, FDA approval, PMA application, clinical study, regulatory compliance, financing, Alumni Capital